Search Results 1131-1140 of 17877 for Assay
Latent tuberculosis infection defined as positive interferon gamma release assay (IGRA), by QuantiFERON-TB Gold testing at Screening. History of clinically ...
Cohort 4 - Patients are required to have known tumor PD-\[L\]1 status determined by local testing using an approved assay. PD-\[L\]1 testing performed prior ...
Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas. Mol Oncol. 2013 Jun; 7(3):732-8. Epub 2013 Mar ...
Qualifying deleterious SPOP mutation detected on any archival genomic assay (tissue and/or liquid biopsy) is acceptable for study inclusion. Qualifying ...
The same platform is being applied to develop cancer subtyping assays. The novel biomarkers resulting from his cancer proteogenomics research will be ...
Ki-67 index of ≥20% (for Cohort 2) on untreated breast tissue as determined by the investigational assay (described in Section 3.2.1) at the Study JPCF ...
... assay following trauma: A pilot study. Res Pract Thromb Haemost. 2021 Mar; 5 (3):395-402 Epub 2021 Mar 08. View PubMed; Buckarma E, Rivera M, Schiller H ...
... assay. Locally advanced or metastatic breast cancer with either measurable (according to RECIST 1.1 [Eisenhauer, et al, 2009]) or non-measurable lesions ...
Tumor PD-L1 status, confirmed by a reference laboratory using the Ventana SP263 PD-L1 immunohistochemistry (IHC) assay, must be known prior to randomization.
... assay. And ≥ 2 seizures per week (mean of total over 1 week); And duration of epilepsy < 3 years; Male or female between the ages of 18 and 85 years of age ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!